Researchers have determined that type II innate lymphoid cells (ILC2s), a type of immune cell, can change its characteristics and functions after a cancer patient receives stem cells from a donor, thereby preventing an effective, healthy rebuilding of the immune system. This new understanding of ILC2 cells’ transformational flexibility could lead to better strategies for enhancing immune system recovery post-transplantation and potentially improve outcomes for transplant recipients.
Source:
www.sciencedaily.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
